---
document_datetime: 2024-04-11 13:15:18
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/febuxostat-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: febuxostat-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.2978585
conversion_datetime: 2025-12-24 16:55:41.010957
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Febuxostat Viatris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0021               | Transfer of Marketing Authorisation                                                             | 01/03/2024                          | 09/04/2024                                  | SmPC, Labelling and PL           |           |
| IG/1688              | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs | 15/01/2024                          | 05/04/2024                                  | SmPC, Labelling and              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            | PL                     |             |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------|
| IB/0019     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/05/2023 | 05/04/2024 | SmPC                   |             |
| IAIN/0018/G | application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 24/04/2023 | 05/04/2024 | SmPC, Labelling and PL | This was an |
| N/0017      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/03/2023 | 05/04/2024 | PL                     |             |

<div style=\"page-break-after: always\"></div>

| IA/0016/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites   | 16/02/2023   | n/a        |                        | (excluding manufacturer   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------|
| IB/0015     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                              | 30/09/2022   | 24/02/2023 | SmPC, Labelling and PL |                           |
| IB/0014     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                | 26/04/2022   | 24/02/2023 | SmPC and PL            |                           |
| II/0012     | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                 | 24/03/2022   | n/a        |                        |                           |
| IB/0013     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                | 09/03/2022   | 24/02/2023 | SmPC, Labelling and PL |                           |

<div style=\"page-break-after: always\"></div>

| R/0011    | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 16/12/2021   | 16/02/2022   | SmPC, Annex II, Labelling and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Febuxostat Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0010    | Transfer of Marketing Authorisation                                                                                                                                                                                                                          | 11/08/2021   | 22/09/2021   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                  |
| IAIN/0009 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                       | 23/04/2020   | 25/11/2020   | Annex II and PL                    |                                                                                                                                                                                                                                                                                  |
| IB/0008   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 12/12/2019   | 25/11/2020   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                  |
| IA/0006   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                   | 06/05/2019   | n/a          |                                    |                                                                                                                                                                                                                                                                                  |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 13/03/2019   | 06/06/2019   | PL                                 |                                                                                                                                                                                                                                                                                  |
| IB/0004/G | This was an application for a group of variations.                                                                                                                                                                                                           | 14/01/2019   | n/a          |                                    |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.4.z - Change to in-process tests or limits   |            |            |                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0003/G | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/11/2018 | 06/06/2019 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| finished product - Change container - Solid, semi-solid pharmaceutical forms B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in the tablets, ampoules, etc.) the range of the currently   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   |            |            |             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0002 | Update of sections 4.4,4.5 and 5.3 of the SmPC in order to reflect the results of preclinical study MRPO- 2015-PKM-005 'Pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral administration of febuxostat or allopurinol\" and clinical study REP-POPPK-MRP-2015-PKM-005 'population pharmacokinetic analysis from study titled pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral                                                                                                                                                                                                                                                                                                                                                      | 12/09/2018 | 06/06/2019 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|           | administration of febuxostat or allopurinol', investigating the drug-drug interaction with azathioprine when co-administered with febuxostat. The Package Leaflet has been adapted accordingly. The changes are performed in line with the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IAIN/0001 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                   | 28/06/2018 | 06/06/2019 | SmPC and PL |